Hormone Mix Could Cut Breast Cancer Risk And Treat Symptoms Of Menopause
Posted on: Tuesday, 20 October 2009, 14:18 CDT
The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21.
Women in menopause who have symptoms, but have not had a hysterectomy are currently treated with a combination of estrogen plus progestin hormone therapy, but this treatment comes with side effects, including a higher risk of breast cancer caused by the progestin.
To find a better way of administering hormone therapy without the breast cancer risk, Hugh S. Taylor, M.D., professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, and his colleagues treated breast and endometrial cell lines with either estrogen or estrogen plus one of the SERMs. The team then looked at various markers of cell growth, including proliferating cell nuclear antigen (PCNA), one of the best-characterized markers of cell growth. The team found that PCNA was increased when they stimulated cells with estrogen and decreased when they added a SERM, indicating that the SERM blocked cell growth.
Taylor said that breast and uterine cells won't be stimulated by the estrogen plus SERM combination, so women in menopause get the benefits of estrogen without the risk of progestin. Progestin is a double-edged sword, Taylor said. It poses a breast cancer risk, but if you use estrogen alone without progestin, there is a higher risk of uterine cancer. SERMs appear to be a good substitute for progestin.
"In our study, the right combination of estrogen and various SERMs was able to prevent the proliferation of breast and endometrial cells, said Taylor." These preliminary findings could lead to a better way of administering hormone therapy to women in menopause."
These laboratory results are currently being tested in large-scale clinical trials.
---
On the Net:
Related Articles
- ZymoGenetics Presents Interim IL-21 Phase 2 Results in Renal Cell Cancer
- Philips and Celsion Announce Research Agreement to Develop New Cancer Treatment That Combines Ultrasound, Drug Delivery Technology
- Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Used in Combination With Ipilimumab
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined With Nexavar(R)
- ZymoGenetics Begins Phase 1/2 Clinical Trial With IL-21 and Nexavar in Patients With Renal Cell Cancer
- Pivotal Research Results Point to New Standard of Care That Reduces Risk of Esophageal Cancer; Photofrin(R) Photodynamic Therapy Spotlighted in October GIE Journal
- Exposure to Sunlight May Decrease Risk of Prostate Cancer
- C-Reactive Protein Levels Are Not Associated With Increased Risk for Colorectal Cancer in Women
- Hormones May Raise Risk of Ovarian Cancer
 |
 |
User Comments (0)
RSS Feeds